These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21543784)

  • 21. Anesthesia Information Management Systems: An Underutilized Tool for Outcomes Research.
    Deng F; Hickey JV
    AANA J; 2015 Jun; 83(3):189-95. PubMed ID: 26137760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Definitions of anaesthetic technique and the implications for clinical research.
    Armstrong RA; Mouton R
    Anaesthesia; 2018 Aug; 73(8):935-940. PubMed ID: 29280142
    [No Abstract]   [Full Text] [Related]  

  • 24. Topics in Study Design and Analysis for Multistage Clinical Proteomics Studies.
    Zeng IS
    Methods Mol Biol; 2016; 1362():29-61. PubMed ID: 26519168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the high-risk patient for carotid endarterectomy: an analysis of the prospective National Surgical Quality Improvement Program database.
    Stoner MC; Abbott WM; Wong DR; Hua HT; Lamuraglia GM; Kwolek CJ; Watkins MT; Agnihotri AK; Henderson WG; Khuri S; Cambria RP
    J Vasc Surg; 2006 Feb; 43(2):285-295; discussion 295-6. PubMed ID: 16476603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
    Pfirrmann M; Hochhaus A; Lauseker M; Saussele S; Hehlmann R; Hasford J
    Leukemia; 2011 Sep; 25(9):1433-8. PubMed ID: 21597465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blinded assessment of treatment effects for survival endpoint in an ongoing trial.
    Xie J; Quan H; Zhang J
    Pharm Stat; 2012; 11(3):204-13. PubMed ID: 22337644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the analysis of composite measures of quality in medical research.
    Moineddin R; Meaney C; Grunfeld E
    Stat Methods Med Res; 2017 Apr; 26(2):633-660. PubMed ID: 25296866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint.
    Bakal JA; Westerhout CM; Cantor WJ; Fernández-Avilés F; Welsh RC; Fitchett D; Goodman SG; Armstrong PW
    Eur Heart J; 2013 Mar; 34(12):903-8. PubMed ID: 23257948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: the evolving role of information technology in perioperative patient safety.
    Stabile M; Cooper L
    Can J Anaesth; 2013 Feb; 60(2):119-26. PubMed ID: 23224715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key issues in end point selection for heart failure trials: composite end points.
    Neaton JD; Gray G; Zuckerman BD; Konstam MA
    J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36.
    Walters SJ
    Health Qual Life Outcomes; 2004 May; 2():26. PubMed ID: 15161494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus conference on a composite endpoint for clinical trials on immunosuppressive drugs in lung transplantation.
    Monchaud C; Marin B; Estenne M; Preux PM; Marquet P;
    Transplantation; 2014 Dec; 98(12):1331-8. PubMed ID: 25437102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations.
    Brown PM; Anstrom KJ; Felker GM; Ezekowitz JA
    Can J Cardiol; 2016 Nov; 32(11):1356.e21-1356.e28. PubMed ID: 27499377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?
    Laporte S; Diviné M; Girault D;
    Therapie; 2016 Feb; 71(1):27-41. PubMed ID: 27080628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consistency-ensured parametric tests for critical events of composite endpoints.
    Huque MF; Alosh M; Guerra M
    J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inconsistent selection and definition of local and regional endpoints in breast cancer research.
    Moossdorff M; van Roozendaal LM; Schipper RJ; Strobbe LJ; Voogd AC; Tjan-Heijnen VC; Smidt ML
    Br J Surg; 2014 Dec; 101(13):1657-65. PubMed ID: 25308345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.